Table 1.

Summary of the type of treatments, treatment responses and survival outcomes in patients with T-PLL (frontline and salvage setting)

	Alemtuzumab monotherapy		Alemtuzumab + pentostatin		Nelarabine
	First line	Salvage	First line	Salvage	All
	n = 42	n = 15	n = 13	n = 5	n = 5 (one frontline and four salvage)
Overall response (%)	81	46	82	75	20
Complete response (%)	61	46	73	50	0
Median OS (months)*	15	15	10.4	2.6	2
Median PFS (months)*	11	3	4.3	2.6	2
Median number of prior regimen (range)	–	1 (1–4)	–	3 (1–3)	2 (1–3)

^*Censored at stem cell transplant, total of 29 patients were treated with salvage therapy and shown above is information on 24 patients, 5 patients were treated with miscellaneous treatments (Fordosine, HyperCVAD, fludarabine-based regimen).